University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Harold Collard, M.D.

Director of the Interstitial Lung Disease Program

Dr. Harold R. Collard is an assistant professor of medicine in the Division of Pulmonary and Critical Care Medicine and the director of the Interstitial Lung Disease Program at UCSF Medical Center. His primary interest is in the management of patients with interstitial lung disease, including how best to diagnose and treat interstitial lung disease and how the condition impacts a patient's quality of life and survival.

Collard earned a medical degree at Duke University. He completed an internship, residency and chief residency in internal medicine at UCSF as well as a fellowship in pulmonary and critical care medicine at the University of Colorado. Prior to joining UCSF, Collard was a member of the Interstitial Lung Disease Program at the National Jewish Medical and Research Center in Denver.


Interstitial Lung Disease Program
400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143
Phone: (415) 353-2577
Fax: (415) 353-2568

Hours: Friday
8 a.m. – noon

Pulmonary Practice at Parnassus
400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143-0359
Phone: (415) 353-2961
Fax: (415) 353-2568

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Harold Collard


Duke University School of Medicine 1997


UCSF Medical Center, Internal Medicine 2000


University of Colorado Medical Center 2004

Selected Research and Publications

  1. Harari S, Humbert M, Blasi F, Collard HR, Matucci-Cerinic M, Simonneau G, Vancheri C, Wells AU, Cottin V. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Eur Respir Rev. 2015 Sep; 24(137):375-7.
  2. Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015 Aug; 46(2):512-20.
  3. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015 Jul 15; 192(2):e3-e19.
  4. Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, Raghu G. Health Care Utilization and Costs of Idiopathic Pulmonary Fibrosis in U.S. Medicare Beneficiaries Aged 65 Years and Older. Ann Am Thorac Soc. 2015 Jul; 12(7):981-7.
  5. Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med. 2015 Aug; 109(8):1058-62.
  6. Corte TJ, Collard H, Wells AU. Idiopathic interstitial pneumonias in 2015: A new era. Respirology. 2015 Jul; 20(5):697-8.
  7. Collard HR. Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis. Eur Respir J. 2015 May; 45(5):1218-20.
  8. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J. 2015 Jul; 46(1):243-9.
  9. Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015 May; 3(5):388-96.
  10. Mazzei ME, Richeldi L, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2015 Jun; 9(3):121-9.
  11. Johannson KA, Balmes JR, Collard HR. Air pollution exposure: a novel environmental risk factor for interstitial lung disease? Chest. 2015 Apr 1; 147(4):1161-7.
  12. Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015 Jan 22.
  13. Spagnolo P, Wells AU, Collard HR. Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discov Today. 2015 May; 20(5):514-24.
  14. Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest. 2014 Nov 1; 146(5):1256-62.
  15. White ES, Brown KK, Collard HR, Conoscenti CS, Cosgrove GP, Flaherty KR, Leff JA, Martinez FJ, Roman J, Rose D, Violette S, Kaminski N. Open-access biorepository for idiopathic pulmonary fibrosis. The way forward. Ann Am Thorac Soc. 2014 Oct; 11(8):1171-5.
  16. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014 Nov 1; 307(9):L681-91.
  17. DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, Kauder SE, Biswas S, Karnik SK, Ha C, Modrusan Z, Matthay MA, Kukreja J, Collard HR, Egen JG, Wolters PJ, Arron JR. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax. 2015 Jan; 70(1):48-56.
  18. Ryerson CJ, Collard HR. Acute exacerbations complicating interstitial lung disease. Curr Opin Pulm Med. 2014 Sep; 20(5):436-41.
  19. Ryerson CJ, Corte TJ, Collard HR, Richeldi L. A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J. 2014 Aug; 44(2):273-6.
  20. Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, Collard HR, Ryerson CJ. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014 Aug; 146(2):422-36.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.